ProQR Therapeutics N.V. (PRQR)
1.65
0.00 (0.00%)
At close: Mar 24, 2025, 3:59 PM
1.64
-0.58%
After-hours: Mar 24, 2025, 04:07 PM EDT
ProQR Therapeutics Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
| Revenue | 18.91M | 6.51M | 4.04M | 1.35M | n/a | 1.93M | 4.94M | -1.53M | 2.28M | 9.41M | 313K | n/a |
| Cost of Revenue | n/a | 133.52K | 2.48M | n/a | 2.19M | 116.82M | 983.51K | 1M | 1.28M | 482.85K | n/a | n/a |
| Gross Profit | 18.91M | 6.38M | 1.56M | 1.35M | -2.19M | -114.89M | 3.96M | -2.53M | 1M | 8.92M | 313K | n/a |
| Operating Income | -30.47M | -31.86M | -64.72M | -57.19M | -42.37M | -57.45M | -36.29M | -40.5M | -39.57M | -27M | -16.46M | -3.24M |
| Interest Income | 3.25M | 2.59M | 106K | 5K | 313K | 402K | -792K | -3.17M | 470K | 6.17M | 4.33M | 24K |
| Pretax Income | -27.96M | -27.81M | -64.8M | -61.56M | -46.49M | -56.61M | -37.09M | -43.67M | -39.1M | -20.83M | -12.13M | -3.25M |
| Net Income | -27.76M | -28.12M | -64.89M | -61.68M | -46.61M | -56.75M | -36.89M | -43.64M | -39.1M | -20.83M | -12.13M | -3.25M |
| Selling & General & Admin | 13.66M | 16.24M | 18.65M | 17.37M | 13.69M | 12.89M | 12.54M | 10.84M | 9.48M | 6.84M | 6.51M | 786K |
| Research & Development | 36.36M | 25.15M | 50.87M | 42.22M | 38.13M | 46.49M | 29.51M | 31.15M | 31.92M | 23.4M | 10.27M | 2.57M |
| Other Expenses | -640K | -3.01M | -765K | -1.04M | 9.37M | 1.93M | 5.76M | 1.5M | 1.83M | 3.23M | 313K | n/a |
| Operating Expenses | 49.38M | 38.37M | 68.75M | 58.55M | 51.82M | 59.38M | 42.05M | 41.99M | 41.4M | 30.24M | 16.77M | 3.24M |
| Interest Expense | 1.08M | 1.2M | 5.13M | 3.4M | 2.04M | 1.08M | 810K | 596K | 538K | 395K | 265K | 38K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 49.38M | 38.37M | 68.75M | 58.55M | 51.82M | 59.38M | 42.05M | 41.99M | 41.4M | 30.24M | 16.77M | 3.24M |
| Income Tax | -197K | -78K | 96K | 117K | 124K | 132K | 1K | 2K | -470K | -6.17M | -4.33M | 24K |
| Shares Outstanding (Basic) | 81.67M | 81.01M | 71.64M | 64.18M | 50.06M | 41.04M | 34.05M | 25.37M | 23.35M | 23.34M | 11.08M | 22.21M |
| Shares Outstanding (Diluted) | 81.67M | 81.01M | 71.64M | 64.18M | 50.06M | 41.04M | 34.05M | 25.37M | 23.35M | 23.34M | 11.08M | 22.21M |
| EPS (Basic) | -0.34 | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -1.09 | -0.15 |
| EPS (Diluted) | -0.34 | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -1.09 | -0.15 |
| EBITDA | -24.12M | -24.1M | -56.46M | -54.95M | -136.56M | -174.27M | -35.29M | n/a | -120.55M | -84.24M | -49.7M | -3.19M |
| Depreciation & Amortization | 2.76M | 2.51M | 2.48M | 2.42M | 2.19M | 2.05M | 983.51K | 1M | 1.28M | 480K | 126K | 24K |